-
Therapeutics and Clinical Risk Management
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Beta-adrenergic receptor antagonists and chronic heart failure in children
(2097) Views (476) Full article downloads
Authors: Sylvie Di Filippo
Published Date November 2007
Volume 2007:3(5) Pages 847 - 854
DOI: http://dx.doi.org/10.2147/TCRM.S
Sylvie Di Filippo
Department of Pediatric Cardiology, Hopital Cardiovasculaire et Pneumologique Louis Pradel, Lyon, France
Abstract: Chronic congestive heart failure (HF) occurs in infants and children as a result of systemic ventricle incompetence. Neurohormonal activation is thought to be the main consequence of cardiac pump failure and cause of further worsening. Several large multicenter randomized trials have demonstrated that beta-adrenergic blocking agents can improve ventricular ejection fraction, symptoms, and survival in adults with chronic congestive HF. Current literature about pediatric HF is very scarce. The only large, multicenter, randomized, placebo-controlled pediatric trial failed to demonstrate any beneficial effect of beta-blockers in infants and children with chronic HF. Other small-size reports showed significant improvement in ejection fraction and/or clinical outcomes. The HF pediatric population is characterized by wide heterogeneicity regarding causes, underlying cardiac disease, drug pharmacokinetics, and interactions, which may account for divergences. Further large-scale studies are needed to elucidate the optimal use (indications and dosages) of beta-blockers in the management of HF in children, with particular attention to the underlying cardiac disease.
Keywords: heart failure, children, beta-blockers, carvedilol
Readers of this article also read:
Selective COX-2 inhibitors, NSAIDs and cardiovascular events – is celecoxib the safest choice?
Oblimersen for the treatment of patients with chronic lymphocytic leukemia
Montelukast: its role in the treatment of childhood asthma
Pharmacokinetics of morphine and oxycodone following intravenous administration in elderly patients
Prevalence, clinical significance, and management of peripheral arterial disease in women: is there a role for postmenopausal hormone therapy?
Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome
Colon-targeted delivery of live bacterial cell biotherapeutics including microencapsulated live bacterial cells
Adult patients with pulmonary arterial hypertension due to congenital heart disease: a review on advanced medical treatment with bosentan
Clinical utility of esomeprazole for treatment of gastroesophageal reflux disease in pediatric and adolescent patients
- Have an opinion about one of our articles?
We encourage you to write a Letter to the Editor
- American Acne and Rosacea Society
The American Acne and Rosacea Society (AARS), is a 501(c)(6) non-profit organization dedicated to elevating the understanding and treatment of acne and rosacea.
- The benefits and risks of testosterone replacement therapy: a review
- Tenofovir-associated bone density loss
- Drug design with Cdc7 kinase: a potential novel cancer therapy target
- Development of mucosal adjuvants for intranasal vaccine for H5N1 influenza viruses




